Variations in the peroxisome proliferator-activated receptor-γ gene and melanoma risk

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Letters

• Publication date

  2007-02-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CANLET.2006.02.022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene

  2005cited by this paper
• Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study.

  2005cited by this paper
• Journal of Carcinogenesis BioMed Central Review Estrogen, mitochondria, and growth of cancer and non-cancer cells

  2005cited by this paper
• Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor γ

  2004cited by this paper
• Cardiovascular Risk in Type 2 Diabetes Is Associated With Variation at the PPARG Locus: A Go-DARTS Study

  2004cited by this paper
• Variations in the genes encoding the peroxisome proliferator-activated receptors α and γ in psoriasis

  2004cited by this paper
• Peroxisome-proliferator-activated receptors and cancers: complex stories

  2004cited by this paper
• Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes

  2004cited by this paper
• Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure

  2004cited by this paper
• Genetic epidemiology of melanoma.

  2003cited by this paper
• Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction

  2003cited by this paper
• Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer.

  2003cited by this paper
• Association testing by DNA pooling: An effective initial screen

  2002cited by this paper
• Agonists of Peroxisome Proliferator-Activated Receptor γ Inhibit Cell Growth in Malignant Melanoma

  2002cited by this paper
• PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

  2002cited by this paper
• The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism

  2002cited by this paper
• Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma.

  2001cited by this paper
• Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma.

  2001cited by this paper
• Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases

  2001cited by this paper
• Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color.

  2001cited by this paper
• Genetics of familial and sporadic melanoma

  2000cited by this paper
• Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?

  2000cited by this paper
• Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population

  2000cited by this paper
• Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.

  2000cited by this paper
• Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease

  1999cited by this paper
• CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas

  1999cited by this paper
• PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter

  1998cited by this paper
• A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

  1998cited by this paper
• Peroxisome proliferator-activated receptors, orphans with ligands and functions.

  1997cited by this paper

• Genetic polymorphisms of PPAR genes and human cancers: evidence for gene–environment interactions

  2019cites this paper
• PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis

  2017cites this paper
• Prevalence of the rs1801282 single nucleotide polymorphism of the PPARG gene in patients with metabolic syndrome.

  2015cites this paper
• Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis

  2013cites this paper
• In vivo imaging reveals selective PPAR activity in the skin of peroxisome proliferator‐activated receptor responsive element‐luciferase reporter mice

  2013cites this paper
• No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case–control study

  2012cites this paper
• Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case–control study

  2009cites this paper
• Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin

  2008cites this paper
• PPARs Mediate Lipid Signaling in Inflammation and Cancer

  2008cites this paper
• ReviewArticle PPARs Mediate Lipid Signaling in Inflammation and Cancer

  2008cites this paper
• Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology Published, JLR Papers in Press, January 8, 2008.

  2008cites this paper